RJFSA
VIR icon

Raymond James Financial Services Advisors’s Vir Biotechnology VIR Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,647
Closed -$258K – 3270
2020
Q4 		$258K Sell
9,647
-9,540
-50% -$310K ﹤0.01% 2554
2020
Q3 		$659K Sell
19,187
-11,077
-37% -$477K ﹤0.01% 1807
2020
Q2 		$1.24M Buy
+30,264
New +$1.02M ﹤0.01% 1358

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Raymond James Financial Services Advisors's VIR Position: Q1 2021 in Review

Raymond James Financial Services Advisors sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 9,647 shares — an estimated $258K sold.

Raymond James Financial Services Advisors first reported a position in VIR in Q2 2020 and held it in 3 quarters. The position peaked at $1.24M in Q2 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Raymond James Financial Services Advisors reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 9,647 Vir Biotechnology shares in Q1 2021, an estimated $258K.
  • Raymond James Financial Services Advisors first reported a position in Vir Biotechnology in Q2 2020 and held it in 3 quarters.
  • Raymond James Financial Services Advisors's Vir Biotechnology position peaked at $1.24M in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2021, filed 14 May 2021.